Despite the impressive efficacy of the PD-1/PD-L1 blockade in patients with tumors resistant to conventional cancer therapy, this anti-PD-1/PD-L1 therapy is still unsatisfactory as most patients do not respond to it. Here, CD274 is linked to cancer.